Last reviewed · How we verify

NCT07258329

Screening for Intrapartum Fetal Compromise Using Placental Biomarkers

Recruiting now Last updated 2 December 2025
What this trial tests

trial in Pregnant Women in 428 participants. Currently enrolling.

Timeline
28 March 2025
Primary endpoint
1 February 2028
1 October 2028

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment428
Start date28 March 2025
Primary completion1 February 2028
Estimated completion1 October 2028
Sites2 locations across Italy

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, female only, with Pregnant Women. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the association between placental markers (sFlt-1, PlGF, and the sFlt-1/PlGF ratio) and intrapartum fetal compromise, assessed on the basis of the cardiotocographic tracing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pregnant Women

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07258329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing